Baxalta Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Jutta Schreiner

Peter Turecek

Hans-Peter Schwarz

Hanspeter Rottensteiner

Katalin Varadi

The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.

Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)

The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.

Methods of measuring adamts 13 activity

Methods of measuring ADAMTS 13 activity

Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor

Method for testing treatment of ADAMTS13 deficiency

Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof

Growing community of inventors

Vienna, Austria

Jutta Schreiner